Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UI-103
- Development stage
- Preclinical
- Lead developer
- United Immunity
- Modality
- Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
UI-103 is an off-the-shelf, in vivo chimeric antigen receptor-macrophage (CAR-M) therapy being developed by United Immunity. It utilizes the company's proprietary Myeloid Targeting Platform™, specifically a PEG-free, pullulan-coated lipid nanoparticle (P-LNP) delivery system, to selectively deliver chimeric antigen receptor (CAR) mRNA to disease-associated myeloid cells (such as tumor-associated macrophages and dendritic cells) via the DC-SIGN receptor. This in vivo engineering approach is designed to generate CAR-expressing macrophages directly within the patient's body, avoiding the high manufacturing costs and complexity of ex vivo cell therapies. UI-103 is being developed for the treatment of solid tumors and autoimmune diseases (including B-cell depletion), with preclinical development underway and IND filing planned.
- Other names
- in vivo CAR-M therapyin vivo CAR-Macrophage therapyin vivo CAR-macrophages P-LNP
Beyond the preview
Go deeper on UI-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UI-103.